303 Comparison of Antifungal Activities of Efinaconazole and Conventional Antifungal Agents against Dermatophytes and Yeasts

As growing the number of aging population and immunocompromised patients, there has been an increase in patients with skin fungal infections. Trichophyton rubrum, Trichophyton mentagrophytes and Candida albicans are known as the key pathogen of superficial dermatomycosis. Although itraconazole, terbinafine, amorolfine, and ciclopirox have been used for the treatment of these infections, they have limitation due to the drug side effects and lack of efficacy. In 2014, the Food and Drug Administration approved efinaconazole as a novel antifungals particular in onychomycosis.

Source: Journal of Investigative Dermatology - August 31, 2019 Category: Dermatology Authors: M. Hur, J. Lee, S. Kim, J. Hong, J. Kim, J. Hong, H. Cheon, Y. Lee, Y. Choe, K. Ahn Tags: Genetics and Cell Based Therapy Source Type: research